RNA Technologies Expand Tool Kit for Cancer Immunotherapy

Elie Dolgin • October 1, 2019

Multiple companies are pursuing mRNA-based medicines that harness the body's protein-making machinery to transform lab-synthesized nucleotides into cancer-associated antigens, in the case of vaccines, or immune-stimulating molecules, in the case of therapeutics. Several candidates from BioNTech and Moderna have shown promise in early-stage testing.

Continue reading at Cancer Discovery.

Tubes of blood, one looks like an hourglass but with a woman's head
By Elie Dolgin April 16, 2025
Circulating biomarkers are quickly becoming a crucial part of diagnosis and disease monitoring for physicians, researchers — and even some consumers.
Zebra wearing video camera-equipped collar
By Elie Dolgin February 13, 2025
Zebras and giraffes offer one another protection without food competition.